ישראל - עברית - Ministry of Health

masrouji co, ltd - cefadroxil as monohydrate - קפסולות - cefadroxil as monohydrate 500 mg - cefadroxil

ישראל - עברית - Ministry of Health

medison pharma ltd - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 500 u/vial - botulinum toxin

ישראל - עברית - Ministry of Health

takeda israel ltd - factor viii inhibitor bypassing fraction - אבקה וממס להכנת תמיסה להזרקה\אינפוזיה - factor viii inhibitor bypassing fraction 500 u/vial - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - for the control of bleeding episodes in haemophilia a patients with factor viii inhibitors and also in patients with acquired factor viii inhibitors.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - cilastatin sodium 500 mg/vial; imipenem as monohydrate 500 mg/vial - powder for solution for injection - imipenem and enzyme inhibitor - infections caused by susceptible microorganisms.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - metformin hydrochloride 500 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - metformin hydrochloride 500 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - metformin hydrochloride 500 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

ישראל - עברית - Ministry of Health

novo nordisk ltd - metformin hydrochloride 500 mg; repaglinide 1 mg - tablets - metformin - novogard is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 mellitus who are already treated with a meglitinide and metformin hcl or who have inadequate glycemic control on a meglitinide alone or metformin hcl alone.

ישראל - עברית - Ministry of Health

novo nordisk ltd - metformin hydrochloride 500 mg; repaglinide 2 mg - tablets - metformin - novogard is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 mellitus who are already treated with a meglitinide and metformin hcl or who have inadequate glycemic control on a meglitinide alone or metformin hcl alone.

ישראל - עברית - Ministry of Health

novartis pharma services ag - metformin hydrochloride 500 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.